- AU$8.58bn
- AU$8.60bn
- AU$2.35bn
Australia's Cochlear tanks on potential order cancellations, revised annual outlook
Cochlear plunges nearly 39% after earnings forecast cut on MidEast‑led demand worries (updated)
Cochlear cuts fiscal 2026 earnings outlook on Middle East‑led demand uncertainty
Australia's Cochlear enters recruiting phase for implant trial, Citi says
Cochlear shares plunge, flags annual earnings at lower end of outlook (updated)
Cochlear logs worst day in nearly 6 years on flagging FY earnings at lower end of outlook
Cochlear flags annual earnings at lower end of outlook, shares tank 16%
Brief: Cochlear Posts H1 Adjusted Net Income A$194.8 Million
Morningstar sees Australia's Cochlear shares as slightly overvalued
Australia's Cochlear opts out of healthcare rally after Citi downgrade
Morningstar sees moderating unit sales growth for 'overvalued' Cochlear
Australia's Cochlear rises on higher annual profit, share buyback
Brief: Cochlear Approved Buyback Of Up To A$75 Mln In Shares
Brief: Cochlear Says Co Receives FDA Approval For New Nucleus Nexa System
Brief: Cochlear Says It Launched New Cochlear Implant System
Brief: Cochlear Updates FY25 Earnings Guidance To A$390-400 Mln
Australia's Cochlear reverses losses; lowers earnings outlook
Australia's Cochlear rebounds from day's losses, addresses U.S. tariffs
Brief: Cochlear Confirms Will Continue To Be Able To Rely On A Chapter Of Harmonized Tariff Schedule Of U.S.